The Week in Review: China Working on Biotech Development Plan
publication date: Jun 5, 2010
|
author/source: Richard Daverman, PhD
China is close to finalizing a draft proposal of a five-year plan for developing its biotech industry (see story). The draft will be written by China’s top economic planning agency and submitted to the State Council, the nation’s highest ruling body. Thus far, no details of the plan have been publicly disclosed.
Pfizer (NYSE: PFE) reached a deal to sell its China swine vaccine business to Harbin Pharmaceutical Group (SHEX: 600664), the highest bidder, for $50 million (see story). Pfizer was ordered to divest the business as part of China’s approval of its merger with Wyeth last year. Harbin is the largest pharmaceutical company in China and a major force in China's antibiotics sector.
Huiheng Medical (OTCBB: HHGM), a company that makes radiation equipment for the treatment of cancer, agreed to buy Portola Medical, Inc. (see story). Portola owns the global rights to manufacture and market the ClearPath™ breast brachytherapy system. Huiheng plans to market the device in China as well as the rest of the world. ClearPath has been approved for use in the US.
Mindray Medical (NYSE: MR) signed a non-exclusive license with Pulsion Medical Systems of Germany, allowing Mindray to incorporate two of Pulsion’s technologies into Mindray’s patient monitoring systems (see story). PiCCO monitors cardiovascular functions in critically ill patients, and CeVOX tracks a patient’s oxygen balance. Financial details were not disclosed.
Beijing Tiantan Biological Products (SHSE: 600161), a biopharmaceutical company, is developing a 2.7 billion RMB ($400 million) biological vaccine production facility in the Beijing Economic-Technological Development Area (BDA) (see story). The company makes vaccines, blood-related products and diagnostic devices. One of its major product lines is hepatitis B vaccines.
Sinovac Biotech (NSDQ: SVA) was selected to supply its hepatitis A vaccine, Healive®, to the Beijing Expanded Program of Immunization (see story). Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The decision was made by the Beijing CDC, which evaluated suppliers on the basis of several criteria, including product quality, service and price. The order was for 477,000 doses.
Disclosure: none.
Pfizer (NYSE: PFE) reached a deal to sell its China swine vaccine business to Harbin Pharmaceutical Group (SHEX: 600664), the highest bidder, for $50 million (see story). Pfizer was ordered to divest the business as part of China’s approval of its merger with Wyeth last year. Harbin is the largest pharmaceutical company in China and a major force in China's antibiotics sector.
Huiheng Medical (OTCBB: HHGM), a company that makes radiation equipment for the treatment of cancer, agreed to buy Portola Medical, Inc. (see story). Portola owns the global rights to manufacture and market the ClearPath™ breast brachytherapy system. Huiheng plans to market the device in China as well as the rest of the world. ClearPath has been approved for use in the US.
Mindray Medical (NYSE: MR) signed a non-exclusive license with Pulsion Medical Systems of Germany, allowing Mindray to incorporate two of Pulsion’s technologies into Mindray’s patient monitoring systems (see story). PiCCO monitors cardiovascular functions in critically ill patients, and CeVOX tracks a patient’s oxygen balance. Financial details were not disclosed.
Beijing Tiantan Biological Products (SHSE: 600161), a biopharmaceutical company, is developing a 2.7 billion RMB ($400 million) biological vaccine production facility in the Beijing Economic-Technological Development Area (BDA) (see story). The company makes vaccines, blood-related products and diagnostic devices. One of its major product lines is hepatitis B vaccines.
Sinovac Biotech (NSDQ: SVA) was selected to supply its hepatitis A vaccine, Healive®, to the Beijing Expanded Program of Immunization (see story). Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The decision was made by the Beijing CDC, which evaluated suppliers on the basis of several criteria, including product quality, service and price. The order was for 477,000 doses.
Disclosure: none.
0 Comments Posted Leave a comment